Topics
Glioblastoma | Treatment | Targeted therapy | Nivolumab
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Nivolumab
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
Skadborg
SK, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F, Pedersen
V, Mann M, Christensen IJ, Skjøth-Rasmussen J, Yde CW,
Kristensen BW, Skovgaard Poulsen H, Hasselbalch B, Svane IM,
Lassen U, Hadrup SR.
Nivolumab
reaches brain lesions in patients with recurrent glioblastoma and
induces T-cell activity and upregulation of checkpoint pathways.
Cancer
Immunol Res.
2024 Jun 18. doi:
10.1158/2326-6066.CIR-23-0959. PMID:
38885356. Observational study. ˍ